PubMed ID:
16129387
Public Release Type:
Journal
Publication Year: 2005
Affiliation: Department of Pharmacy Practice, Hampton University School of Pharmacy, Hampton, Virginia 23668, USA. youlanda.logan@hamptonu.edu
DOI:
https://doi.org/10.1016/s1543-5946(05)00031-0
Authors:
Belgeri MT,
Logan YT
Studies:
Medical Therapy of Prostatic Symptoms
Benign prostatic hyperplasia (BPH) is a medical condition occurring in older men (ie, those aged >60 years) resulting from enlargement of the prostate gland. Consequently, affected men may experience bother-some urinary tract symptoms and diminished quality of life. The risk of lower urinary tract symptoms and complications such as acute urinary retention (AUR) may increase if BPH is untreated. Currently, 2 classes of drugs-alpha-adrenergic blockers (alpha-blockers) and 5alpha-reductase inhibitors-are indicated for the treatment of BPH. Although the 2 classes are commonly used in combination, the evidence has frequently not been supportive of this practice. Results from the Medical Therapy of Prostatic Symptoms (MTOPS) trial, the largest and longest clinical trial on this topic to date, revisited the role of combination therapy in the treatment of BPH.